Alto Neuroscience (NYSE:ANRO) Trading Down 6.4% – Here’s What Happened

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) were down 6.4% on Tuesday . The stock traded as low as $26.24 and last traded at $26.2790. 290,790 shares were traded during trading, a decline of 12% from the average session volume of 329,169 shares. The stock had previously closed at $28.07.

Analyst Ratings Changes

Several brokerages recently commented on ANRO. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Robert W. Baird dropped their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

The company has a market cap of $921.99 million, a PE ratio of -10.86 and a beta of 1.24. The business’s 50 day moving average price is $22.82 and its 200-day moving average price is $20.36. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after buying an additional 211,222 shares during the last quarter. Artia Global Partners LP bought a new position in Alto Neuroscience during the fourth quarter worth $520,000. Perceptive Advisors LLC boosted its holdings in Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after purchasing an additional 1,629,027 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the fourth quarter worth $1,153,000. Finally, Commodore Capital LP bought a new position in shares of Alto Neuroscience in the 4th quarter worth about $32,453,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.